Losartan may stimulate brown fat to improve metabolism

Researchers at Rockefeller University have discovered that losartan, a common medication used to treat hypertension, may stimulate brown adipose tissue (brown fat) to improve metabolism. In studies involving mice, the drug was shown to boost the activity of this tissue, which is linked to enhanced cardiovascular health and, for the first time, potential benefits for psychiatric health.

The findings are supported by an analysis of medical records and PET/CT scans from 100,000 patients at the Memorial Sloan Kettering Cancer Center. By utilizing machine learning to evaluate scans across six body regions, researchers found that patients with higher levels of brown fat activity generally exhibited better glycemic levels, lipid profiles, and lower inflammatory markers.

Additionally, the study noted that the specific location of brown fat activity influences health outcomes; for instance, higher activity in the axillary region was associated with a reduced risk of hypertension. The research suggests that repurposing losartan, an angiotensin receptor blocker (ARB) with a well-established safety profile, could serve as a clinical method for stimulating brown fat.